Interleukin‐2 promotes pegylated interferon alpha for hepatitis B surface antigen loss: A retrospective pragmatic clinical study at the Fourth Affiliated Hospital of Zhejiang University Medical College

BACKGROUND AND AIMS: Interleukin‐2 (IL‐2) can be used as an adjuvant therapy when pegylated interferon alpha (Peg‐IFN‐α) does not effectively promote hepatitis B surface antigen (HBsAg) loss, but the relevant timing, kinetic patterns, and prognostic associations of this intervention are unclear. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Wencai, Wang, Yuming, Huang, Guangyu, Wang, Kaifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662690/
https://www.ncbi.nlm.nih.gov/pubmed/36381411
http://dx.doi.org/10.1002/hsr2.932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662690/
https://www.ncbi.nlm.nih.gov/pubmed/36381411
http://dx.doi.org/10.1002/hsr2.932

Ejemplares similares